Skip to content

Progesterone Support of FET

Progesterone Support for Frozen Embryo Transfer: Intramuscular Versus Vaginal Suppository - A Prospective, Randomized, Controlled Trial

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01058382
Acronym
FETProg
Enrollment
57
Registered
2010-01-28
Start date
2010-02-28
Completion date
2012-10-31
Last updated
2013-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frozen Embryo Pregnancy Rate

Keywords

FET, Progesterone Support, Frozen Embryo Transfer

Brief summary

There have been two very common forms of progesterone administration that have been used during ovulation induction, in vitro fertilization (IVF) and embryo transfers. There are currently no randomized clinical trials to demonstrate which method of progesterone administration is more effective for frozen embryo transfer. We raise the question: Is there a difference between the two accepted methods of progesterone administration, intramuscular and vaginal suppositories, for frozen embryo transfer? Studies for fresh embryo transfer after in vitro fertilization, have demonstrated that there is not a difference between the two methods of progesterone administration. We will evaluate the question for frozen embryo transfer.

Interventions

DRUGProgesterone Vaginal Suppositories

Progesterone Vaginal Suppositories 200 mg three times daily for 10 weeks following embryo transfer

DRUGIntramuscular Progesterone-in-Oil

Progesterone-in-Oil 50 mg IM once daily for 10 weeks following embryo transfer

Sponsors

Charles Coddington
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Females \< 50 years of age * Having frozen embryo transfer at Mayo Clinic * Embryos have been created prior to age 42 * Willing to be randomized to either method of progesterone administration

Exclusion criteria

* Diagnosis of severe medical illness * Uterine lesions affecting the cavity or endometrium * Uterine anomaly * Presence of hydrosalpinx * Extreme difficulty with embryo transfer

Design outcomes

Primary

MeasureTime frame
Clinical Pregnancy Rate3 years

Secondary

MeasureTime frame
Implantation rate3 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026